- Decision: Reject
- Avg Score: 3.67
- Scores: 5, 3, 3
Now I have all the information I need. Let me produce the final consolidated review.

## Summary
This paper presents a preliminary, multi-aspect evaluation of OpenAI's o1 model across 37 medical datasets (35 existing + 2 newly constructed from NEJM and The Lancet), covering three key aspects: understanding, reasoning, and multilinguality. The authors compare o1 against GPT-4, GPT-3.5, MEDITRON-70B, and Llama3-8B, finding that o1 achieves average accuracy improvements of 6.2% over GPT-4 across 19 standard datasets and 8.9% on the two new QA datasets. The paper also identifies weaknesses in o1 (hallucination, inconsistent multilingual reasoning) and highlights issues with evaluation metric reliability.

## Strengths
- **Broad and systematic evaluation scope**: The paper evaluates o1 across 37 datasets spanning understanding (concept recognition, summarization), reasoning (QA, clinical suggestion, agent simulation, medical calculation), and multilinguality — substantially broader than prior medical LLM evaluations that typically focus on isolated factors. This breadth enables a richer picture of o1's capabilities and limitations in medicine.

- **Non-trivial finding about CoT prompting**: Despite o1 having internalized chain-of-thought during training, the paper demonstrates that explicit CoT prompting still yields a 3.18% accuracy boost on knowledge QA tasks (Table 6, Section 4.3), while self-consistency and reflex strategies degrade performance. This provides actionable, model-specific guidance rather than assuming standard prompting techniques are irrelevant.

- **Honest reporting of o1's weaknesses**: The paper transparently documents o1's shortcomings — lower AlignScore (hallucination) than GPT-4 on summarization tasks, struggles with multilingual complex reasoning (1.6% drop vs. GPT-4 on Chinese agent tasks), and datasets where Llama3-8B or GPT-4 outperform o1 (e.g., PMC-Patient: 76.4% vs 96.0%). This balanced reporting strengthens credibility.

- **Identification of metric inconsistency as a methodological challenge**: The paper provides concrete examples where BLEU-1, ROUGE-1, and Mauve produce contradictory model rankings (e.g., o1 beats GPT-4 in ROUGE-L for clinical suggestion but loses in BLEU-1). This contribution extends beyond the specific o1 evaluation to highlight a broader issue in LLM evaluation.

- **Open release of data and outputs**: The paper commits to releasing raw data and model outputs, supporting reproducibility and future research.

## Weaknesses

### Fatal
None.

### Major

- **No statistical rigor for comparative claims**: The paper reports point estimates and percentage differences (6.2%, 6.6%, 8.9%, 3.18%, etc.) and ranks models across datasets without any confidence intervals, standard deviations, or significance tests. Given the number of datasets (37) and comparisons, we cannot assess whether any reported improvement reflects a real difference versus noise. This directly undermines the paper's central quantitative claims. *Example: the paper states o1 surpasses GPT-4 by "an average of 6.2%" — but without uncertainty quantification, this is a single-run point estimate whose stability is unknown.*

- **New datasets lack construction details**: The paper introduces NEJMQA and LancetQA as "newly constructed and more challenging" QA tasks with "greater clinical relevance," and explicitly treats them as a contribution (abstract, Section 3, Section 4.2). Yet it provides essentially zero information about their construction: no dataset size, no selection criteria, no answer verification process, no format specification. For two datasets presented as central to the evaluation, this is a significant transparency gap. The claim that they "translate more effectively into real-world clinical utility" cannot be assessed without knowing what they contain.

### Minor

- **Headline claim exceeds what the evaluation supports**: The paper's title asks "Are We Closer to an AI Doctor?" and Section 4.2 answers "Yes!" — framing that implies progress toward clinical practice competence. However, the evaluation is limited to multiple-choice QA, concept recognition, text summarization, a calculation benchmark, and two simulated clinic environments. Real medical practice involves multimodal data, physical exams, patient interaction, ethical reasoning, and procedural knowledge — none of which are tested. The paper does call itself a "preliminary study" and acknowledges scope limitations, but the "AI doctor" framing in the title and Section 4.2 headline substantially overstates what the evidence supports.

- **Missing per-dataset breakdown for the new datasets**: The paper reports average accuracy on NEJMQA/LancetQA but does not state how many samples each contains or whether results are stable. Combined with the absence of construction details, the two new datasets remain opaque.

- **No error analysis**: The paper reports aggregate AlignScore for hallucination but provides no qualitative analysis of error types — e.g., are o1's hallucinations clinically dangerous? Do they differ in nature from GPT-4's? This would significantly strengthen the contribution beyond aggregate scores.

### Trivial
None.

## Nice-to-Haves
- Reporting exact API parameters (temperature, top_p, max_tokens) for each experiment would improve reproducibility, though this is standard practice often deferred to appendix.
- A small-scale expert review of a random sample of outputs would strengthen the clinical text generation evaluation beyond automated metrics.
- Ablation results for CoT prompting broken down by individual dataset (rather than just the average 3.18% boost) would improve interpretability.

## Removed Points
*These points were identified by reviewers but removed after verification against the paper; they should be treated with caution and not factored into the assessment.*

- **"Metric inconsistency undermines paper's own evaluation":** The harsh critic claimed the paper uses metrics it acknowledges as unreliable. However, the paper uses standard metrics to *demonstrate* the inconsistency problem it then discusses — a valid methodology. Using flawed metrics to surface their flaws is not itself a flaw.

- **"MEDITRON-70B prompting mismatch":** The critic speculates that suboptimal prompting may disadvantage MEDITRON-70B. The paper states it follows the same prompting strategies as prior literature and the benchmarks' own settings. This is speculative and not verified from the paper.

- **"Llama3 outperforming o1 contradicts claimed dominance":** The paper *itself* explicitly reports and discusses this finding (Section 4.3: "no model excels across all tasks"). The paper does not claim universal dominance — it acknowledges trade-offs. This criticism misreads the paper.

- **Missing hyperparameters / reproducibility concerns:** The paper reports following prior work's prompting strategies; temperature/API details are standard to defer. The harsh reviewer's reproducibility complaints about missing trivial implementation details are removed per hard rules.

- **"Missing related work":** Removed per hard rule (no external verification possible).

- **"Yes!" and emoji in section header:** Parser-formatting/style nitpick. Removed.

- **All section-by-section formatting/presentation critiques:** These are too granular and misread the paper (e.g., "dataset descriptions are thin" — the paper references Table 1 which contains dataset descriptions that are stripped by the parser).

## Novel Insights
The most interesting observation emerging from the reviews — and one the paper itself surfaces but does not fully exploit — is that *LLM evaluation metrics themselves may be the bottleneck*: BLEU-1, ROUGE-1, AlignScore, and Mauve can contradict each other on the same outputs, making model rankings partially an artifact of metric choice. Combined with the finding that CoT prompting still helps o1 despite its internalized CoT (but more complex strategies hurt), this suggests that as models become more capable, our evaluation methodology — not just the models — needs fundamental rethinking. The paper's release of raw outputs could enable the community to study this metric disagreement systematically.

## Suggestions
1. **Add statistical rigor**: Report bootstrap confidence intervals or standard deviations for all key metrics. For accuracy-based datasets, include McNemar tests or similar pairwise comparisons between o1 and GPT-4. Without this, the numerical precision in the paper (e.g., "6.2% improvement") is misleading.
2. **Provide full details on NEJMQA and LancetQA**: Dataset size, source selection criteria, question format, answer verification process, and any filtering applied. If these are small or drawn from publicly available quizzes, this context is essential.
3. **Reframe the headline claim**: Replace "AI doctor" framing with a precise statement (e.g., "o1 shows improved performance on a broad set of medical NLP benchmarks, with notable strengths in complex QA and simulation, but also clear weaknesses in hallucination and multilingual reasoning"). This is still a valuable contribution without overreach.
4. **Add a qualitative error analysis**: Characterize the types of hallucinations o1 produces on medical text. Are they clinically dangerous? How do they compare to GPT-4's errors? This would add depth beyond the aggregate AlignScore.
5. **Break down prompting results per dataset**: The 3.18% CoT boost is only reported as an average; showing which datasets benefit most (and least) would make the finding more actionable.
